Skip to main content
Fig. 3 | BMC Medicine

Fig. 3

From: Cost-effectiveness of folic acid therapy for primary prevention of stroke in patients with hypertension

Fig. 3

Cost-effectiveness acceptability curve of enalapril-folic acid versus enalapril. Cost-effectiveness acceptability curve of enalapril-folic acid versus enalapril, for the base case (red line), life year (blue), and scenario analyses: no effect of enalapril-folic acid after 5 years (green); no effect of enalapril-folic acid after 10 years (orange); enalapril-folic acid at 1/2 price (gray). QALY, quality-adjusted life-year

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us